SR
Publicaties op Oncologisch.com
INDUCE-3: A Gerandomiseerde Fase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent...
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, an...
Belantamab mafodotin plus bortezomib and dexamethasone in patiënten met relapsed or refractory multiple myeloma (DREA...
Belantamab mafodotin plus bortezomib-dexamethason bij myeloom: DREAMM-7 fase III
Belantamab mafodotin versus PomDex bij recidief myeloom: DREAMM-3 fase III